Sugi Predict

Sugi Predict / Compounds / SCHEMBL186689

SCHEMBL186689

SCHEMBL186689

N#Cc1c(F)ccc(F)c1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV4 Q9HBA0 3/20 0.42
▸ KDM4E B2RXH2 5/20 0.36
▸ ALDH1A1 P00352 5/20 0.36
▸ HPGD P15428 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ NOTUM Q6P988 1/20 0.34
▸ MAPT P10636 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ CACNA1B Q00975 1/20 0.32
▸ APBA1 Q02410 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ CES2 O00748 1/20 0.32
▸ CES1 P23141 1/20 0.32
▸ TAS1R3 Q7RTX0 1/20 0.32
▸ TAS1R1 Q7RTX1 1/20 0.32
▸ TAS1R2 Q8TE23 1/20 0.32
▸ BCAT1 P54687 1/20 0.32
▸ ESR1 P03372 1/20 0.30
▸ ESR2 Q92731 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27496583 0.89 TRPV4 (0.35) TRPV4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL4323122 0.85 TRPV4 (0.48) TRPV4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL9490088 0.82 TRPV4 (0.43) TRPV4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL7861734 0.82 TRPV4 (0.43) TRPV4NOTUMBCAT1ESR1ESR2
SCHEMBL3652252 0.80 ESR1 (0.42) TRPV4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2597730 0.80 TRPV4 (0.37) TRPV4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL9293702 0.80 TRPV4 (0.37) TRPV4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL16136624 0.80 TRPV4 (0.37) TRPV4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2729265 0.80 TRPV4 (0.37) TRPV4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL1462923 0.80 TAS1R3 (0.38) TRPV4KDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118126051-A Polymorphic substance of mutant BRAF degradation agent and preparation method thereof C4医药公司 2024-06-04 — — CN claimed
CN-113130988-A Electrolyte and electrochemical device using same 深圳市研一新材料有限责任公司 2021-07-16 — — CN claimed
CN-113130989-A Electrolyte and electrochemical device 深圳市研一新材料有限责任公司 2021-07-16 — — CN claimed
CN-113130993-A Electrolyte and electrochemical device thereof 深圳市研一新材料有限责任公司 2021-07-16 — — CN claimed
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 — — US claimed
EP-0608713-B1 2,3-Difluoro-6-introbenzonitrile and 2-chloro-5,6-difluorobenzonitrile, process for their preparation and their use in the preparation of 2,3,6-trifluorobenzoic acid HOECHST AG (DE) 1996-12-27 — — EP claimed
US-5478963-A 2,3-difluoro-6-nitrobenzonitrile and 2-chloro-5,6-difluorobenzonitrile-(2,3-difluoro-6-chlorobenzonitrile), process for their preparation and their use for the preparation of 2,3,6-trifluorobenzoic acid HOECHST AKTIENGESELLSCHAFT (DE) 1995-12-26 — — US claimed
EP-0608713-A1 2,3-Difluoro-6-introbenzonitrile and 2-chloro-5,6-difluorobenzonitrile, process for their preparation and their use in the preparation of 2,3,6-trifluorobenzoic acid HOECHST AKTIENGESELLSCHAFT (DE) 1994-08-03 — — EP claimed
JP-7002751-A — — None — — JP disclosed
EP-4735425-A1 COMPOUNDS Psylo Pty Ltd (AU) 2026-05-06 — — EP disclosed
EP-4263518-B1 NEW QUINAZOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2026-04-01 — — EP disclosed
US-12570615-B2 Quinazolinone derivatives HOFFMANN-LA ROCHE INC. 2026-03-10 — — US disclosed
US-12486253-B2 Therapeutics for the degradation of mutant BRAF C4 THERAPEUTICS, INC. (US) 2025-12-02 — — US disclosed
US-20250353818-A1 Compounds Psylo Pty Ltd (AU) 2025-11-20 — — US disclosed
EP-0608713-B1 2,3-Difluoro-6-introbenzonitrile and 2-chloro-5,6-difluorobenzonitrile, process for their preparation and their use in the preparation of 2,3,6-trifluorobenzoic acid HOECHST AG (DE) 1996-12-27 — — EP disclosed
US-5478963-A 2,3-difluoro-6-nitrobenzonitrile and 2-chloro-5,6-difluorobenzonitrile-(2,3-difluoro-6-chlorobenzonitrile), process for their preparation and their use for the preparation of 2,3,6-trifluorobenzoic acid HOECHST AKTIENGESELLSCHAFT (DE) 1995-12-26 — — US disclosed
JP-H072751-A 2,3-DIFLUORO-6-NITROBENZONITRILE AND 2-CHLORO-5,6-DIFLUOROBENZONITRILE(2,3-DIFLUORO-6-CHLOROBENZONITRILE), THEIR PREPARATION AND THEIR USE FOR PREPARATION OF 2,3,6-TRIFLUOROBENZOIC ACID HOECHST AG 1995-01-06 — — JP disclosed
EP-0608713-A1 2,3-Difluoro-6-introbenzonitrile and 2-chloro-5,6-difluorobenzonitrile, process for their preparation and their use in the preparation of 2,3,6-trifluorobenzoic acid HOECHST AKTIENGESELLSCHAFT (DE) 1994-08-03 — — EP disclosed
EP-0270964-B1 PROCESS FOR OBTAINING SUBSTITUTED FLUOROBENZENES BAYER AG (DE) 1992-07-08 — — EP disclosed
US-4868347-A SOLVENT EXTRACTION BAYER AKTIENGESELLSCHAFT (DE) 1989-09-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12486253-B2 Therapeutics for the degradation of mutant BRAF BRAF, NRAS, KRAS TRPV4 4403/4885KDM4E 1869/4885ALDH1A1 1471/4885
US-20250353818-A1 Compounds NLN, SLC18A2, PYGB TRPV4 2301/4885KDM4E 3243/4885ALDH1A1 981/4885
US-12570615-B2 Quinazolinone derivatives ABL1, NQO2, CNR1 TRPV4 2468/4885KDM4E 2241/4885ALDH1A1 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.